- Merck & Co. Inc.
- Actavis Laboratories
- Barr Laboratories Inc.
- Impax Laboratories Inc.
- Teva Pharmaceutical Industries Ltd.
- Watson Pharma Inc.
- Allergan PLC
- Ivax Corp.
- Biovail Corp.
- Abbott Laboratories Inc.
- Industria Chimica Profarmaco SPA
- Zenith Laboratories Inc.
- Novartis AG
- Mayne Pharma Ltd.
- Purepac Pharmaceutical Co.
- AstraZeneca PLC
- Procter & Gamble Co.
- Pfizer Inc.
- Bristol-Myers Squibb Co.
- Teva Women's Health Inc.
- American BioScience Inc.
- Alza Corp.
- Elan Corp. PLC
- Nektar Therapeutics
- Alkermes PLC
- Mylan Bertek Pharmaceuticals Inc.
- Penederm Inc.
- Reliant Pharmaceuticals Inc.
- DJ Pharma Inc.
- Pharmion Corp.
- CyBear Inc.
- Watson to acquire Schein Pharmaceuticals for $674mm
- Andrx acquires generics pharmaceutical Valmed
- Andrx completes 2.5mm share IPO; raises $26.6mm
- Andrx completes $236mm follow-on offering
- Andrx & Circa form JV on controlled-release generics
- Watson to acquire Circa for nearly $600 million
- Hoechst, Rhone-Poulenc to merge
- Biovail licensed Tiazac to Forest for $75.6mm; deal terminated
- Astra Merck and Procter & Gamble to develop OTC Prilosec
- Mylan Lab completed acq'n of assets of Bertek Inc for $39M
- Mylan Laboratories acquires Penederm in all-stock transaction
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.